132 related articles for article (PubMed ID: 7666614)
21. Potentiation of host defense mechanism against infection by a cytokine inducer, an acyl-MDP derivative, MDP-Lys(L18) (romurtide) in mice and humans.
Azuma I; Otani T
Med Res Rev; 1994 Jul; 14(4):401-14. PubMed ID: 8084203
[No Abstract] [Full Text] [Related]
22. Stimulation of nonspecific resistance to infection induced by muramyl dipeptide analogs substituted in the gamma-carboxyl group and evaluation of N alpha-muramyl dipeptide-N epsilon-stearoyllysine.
Matsumoto K; Otani T; Une T; Osada Y; Ogawa H; Azuma I
Infect Immun; 1983 Mar; 39(3):1029-40. PubMed ID: 6341226
[TBL] [Abstract][Full Text] [Related]
23. Restorative activity of muroctasin on leukopenia associated with anticancer treatment.
Tsubura E; Nomura T; Niitani H; Osamura S; Okawa T; Tanaka M; Ota K; Nishikawa H; Masaoka T; Fukuoka M
Arzneimittelforschung; 1988 Jul; 38(7A):1070-4. PubMed ID: 3190800
[TBL] [Abstract][Full Text] [Related]
24. Induction of tumor necrosis factor-alpha in solid tumor region by the orally administered synthetic muramyl dipeptide analogue, romurtide.
Ueda H; Yamazaki M
Int Immunopharmacol; 2001 Jan; 1(1):97-104. PubMed ID: 11367521
[TBL] [Abstract][Full Text] [Related]
25. Muroctasin. A new muramyl dipeptide derivative, MDP-Lys(L18).
Arzneimittelforschung; 1988 Jul; 38(7A):951-1074. PubMed ID: 3190801
[No Abstract] [Full Text] [Related]
26. Effect of stearoyl-N-acetylmuramyl-L-alanyl-D-isoglutamine on host resistance to Corynebacterium kutscheri infection in cortisone-treated mice.
Ishihara C; Yamamoto K; Hamada N; Azuma I
Vaccine; 1984 Dec; 2(4):261-4. PubMed ID: 6531965
[TBL] [Abstract][Full Text] [Related]
27. Inflammatory cytokine production induced by an analogue of muramyl dipeptide MDP-Lys(L18) in rat macrophage cultures and dog synovial fluid.
Sugawara T; Takada S; Miyamoto M; Nomura M; Kato M
Inflammation; 1996 Feb; 20(1):43-56. PubMed ID: 8926048
[TBL] [Abstract][Full Text] [Related]
28. Restorative effect of romurtide for thrombocytopenia associated with intensive anticancer drug treatment and/or irradiation in patients with gastrointestinal cancer.
Yano K; Matsuoka H; Seo Y; Kounoe S; Saito T; Tomoda H
Anticancer Res; 1995; 15(6B):2883-7. PubMed ID: 8669883
[TBL] [Abstract][Full Text] [Related]
29. Uptake of muramyl dipeptide fluorescent congeners by normal rabbit bronchoalveolar lavage cells: a study using flow cytometry.
Richerson HB; Adams PA; Iwai Y; Barfknecht CF
Am J Respir Cell Mol Biol; 1990 Feb; 2(2):171-81. PubMed ID: 2306373
[TBL] [Abstract][Full Text] [Related]
30. Romurtide, a synthetic muramyl dipeptide derivative, accelerates peripheral platelet recovery in nonhuman primate chemotherapy model.
Namba K; Nitanai H; Otani T; Azuma I
Vaccine; 1996 Oct; 14(14):1322-6. PubMed ID: 9004440
[TBL] [Abstract][Full Text] [Related]
31. [Biochemical and immunological properties of the fractions of tubercle bacilli].
Azuma I
Kekkaku; 1998 Feb; 73(2):65-70. PubMed ID: 9545698
[TBL] [Abstract][Full Text] [Related]
32. Acute toxicity of muroctasin in mice, rats and dogs.
Ono Y; Iwasaki T; Furuhama K; Onodera T
Arzneimittelforschung; 1988 Jul; 38(7A):1022-4. PubMed ID: 3190794
[TBL] [Abstract][Full Text] [Related]
33. Association of interleukin-8 with inflammatory and innate immune components in bronchoalveolar lavage of children with chronic respiratory diseases.
Babu PB; Chidekel A; Shaffer TH
Clin Chim Acta; 2004 Dec; 350(1-2):195-200. PubMed ID: 15530478
[TBL] [Abstract][Full Text] [Related]
34. Enhancement of non-specific resistance to Pseudomonas pneumonia by a synthetic derivative of muramoyl dipeptide in immunosuppressed guinea pigs.
Osada Y; Ohtani T; Une T; Ogawa H; Nomoto K
J Gen Microbiol; 1982 Oct; 128(10):2361-70. PubMed ID: 7153754
[TBL] [Abstract][Full Text] [Related]
35. [Activation of neutrophil function by MDP-Lys(L 18)].
Hirota M; Senju R; Kadota J; Hiratani K; Komori K; Kanda T; Hara K; Hayashi K; Tsuji Y; Watanabe K
Gan To Kagaku Ryoho; 1989 Feb; 16(2):219-24. PubMed ID: 2919891
[TBL] [Abstract][Full Text] [Related]
36. Stimulation of resistance of immunocompromised mice by a muramyl dipeptide analog.
Osada Y; Mitsuyama M; Matsumoto K; Une T; Otani T; Ogawa H; Nomoto K
Infect Immun; 1982 Sep; 37(3):1285-8. PubMed ID: 6752024
[TBL] [Abstract][Full Text] [Related]
37. [Pulmonary immune responses to acute lung injury following smoke inhalation and its mechanisms].
Zhou M; He JS; Li Q; Li T; Liu B; Yan SX; Lu C
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2007 Apr; 19(4):209-13. PubMed ID: 17448273
[TBL] [Abstract][Full Text] [Related]
38. Effect of MDP-Lys(L18) as a mucosal immunoadjuvant on protection of mucosal infections by Sendai virus and rotavirus.
Fukushima A; Yoo YC; Yoshimatsu K; Matsuzawa K; Tamura M; Tono-oka S; Taniguchi K; Urasawa S; Arikawa J; Azuma I
Vaccine; 1996 Apr; 14(6):485-91. PubMed ID: 8782344
[TBL] [Abstract][Full Text] [Related]
39. Effect of L18-MDP(Ala), a synthetic derivative of muramyl dipeptide, on nonspecific resistance of mice to microbial infections.
Osada Y; Mitsuyama M; Une T; Matsumoto K; Otani T; Satoh M; Ogawa H; Nomoto K
Infect Immun; 1982 Jul; 37(1):292-300. PubMed ID: 6809630
[TBL] [Abstract][Full Text] [Related]
40. Aerosol delivery of muramyl dipeptide to rodent lungs.
Pettis RJ; Hall I; Costa D; Hickey AJ
AAPS PharmSci; 2000; 2(3):E25. PubMed ID: 11741241
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
